It is hard to imagine what going blind must be like, so any new technology that restores some sense of vision and shape perception is of tremendous value to those affected.
Pieter Droppert who has worked on ophthalmology clinical trials, comments on the recent news that aptly named, Second Sight, has obtained a CE mark for their Argus II Retinal Prosthesis System; the first device of its kind to be approved.
Obtaining a CE (Conformité Européenne) mark indicates that a medical device has met an appropriate quality and safety standard. The result is that it can be freely marketed and sold throughout the 30 member countries of the European Economic Area (EEA) without any further regulatory approval being necessary. It is a major landmark for any medical device company, equivalent to obtaining FDA approval in the United States.
Further commentary on how Second Sight’s “artificial retina” works and what this “bionic eye” means for those who are blind can be found on Biotech Strategy Blog.